Scarica l'app Stockscreener
15.77
1.02%
0.16
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover - MSN
MoonLake Immunotherapeutics (MLTX) Valuation Check After Mixed Share Price Performance - Yahoo Finance
MoonLake Immunotherapeutics (NASDAQ:MLTX) Institutional Owners May Be Pleased With Recent Gains After 64% Loss Over the Past Year - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Recent Share Price Volatility - simplywall.st
Is MoonLake Immunotherapeutics stock heavily shorted2025 Momentum Check & Weekly High Return Opportunities - mfd.ru
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
BTIG Maintains Buy on MLTX (MoonLake Immunotherapeutics) Feb 2026 - Meyka
BTIG Reiterates Buy Rating for MoonLake (MLTX) with $24 Price Ta - GuruFocus
BTIG Research Reiterates "Buy" Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
BTIG reiterates Buy rating on Moonlake Immunotherapeutics stock ahead of data - Investing.com India
MoonLake Immunotherapeutics: Fast-Track Sonelokimab and Multi-Indication Late-Stage Catalysts Underpin Buy Rating and $32 Target - TipRanks
MoonLake Immunotherapeutics (MLTX) Is Down 7.5% After FDA Fast Track Nod For Sonelokimab In PPP – Has The Bull Case Changed? - simplywall.st
MoonLake Finds Its Footing as FDA Wins Reset the Risk-Reward Profile - Investing.com
Two publications and an FDA fast track designation for Swiss biotechs - Startupticker.ch
(MLTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Assessing Growth Potential with an 18% Upside - DirectorsTalk Interviews
A Look At MoonLake Immunotherapeutics (MLTX) Valuation After Mixed Analyst Calls And FDA Fast Track Decision - simplywall.st
BioTech Breakout: MoonLake Up 30% On FDA Wins - Finviz
MoonLake Immunotherapeutics' (MLTX) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
H.C. Wainwright reiterates Buy rating on Moonlake stock with $32 target - Investing.com Nigeria
MoonLake Immunotherapeutics (NASDAQ:MLTX) Sees Large Growth in Short Interest - MarketBeat
Goldman Sachs Notes VELA-2 Failure, Calls MoonLake Immunotherapeutics (MLTX) a High-Risk Play - Finviz
MoonLake stock surges after FDA grants Fast Track designation for PPP treatment - Investing.com Nigeria
MoonLake Says FDA Grants its Sonelokimab Fast Track Designation for Palmoplantar Pustulosis Treatment - marketscreener.com
MoonLake announces FDA granted Fast Track designation for sonelokimab - TipRanks
MoonLake Immunotherapeutics Receives FDA Fast Track Designation for Sonelokimab in Treating Moderate-to-Severe Palmoplantar Pustulosis - Quiver Quantitative
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day - The Manila Times
FDA Fast Tracks MoonLake drug for severe palmoplantar pustulosis - Stock Titan
Aug Fed Impact: What is the cash position of MoonLake Immunotherapeutics2025 Historical Comparison & Fast Entry High Yield Tips - baoquankhu1.vn
Weekly Earnings: What are the risks of holding Tesla IncQuarterly Trade Report & Short-Term High Return Strategies - baoquankhu1.vn
Aug Opening: What is the Moat Score of MoonLake ImmunotherapeuticsJuly 2025 News Drivers & Growth Focused Entry Point Reports - baoquankhu1.vn
Portfolio Update: Does MoonLake Immunotherapeutics have declining or rising EPSBreakout Watch & Weekly High Return Forecasts - baoquankhu1.vn
How MoonLake Immunotherapeutics stock performs in weak economyWeekly Gains Report & Short-Term Trading Opportunity Alerts - mfd.ru
Can MoonLake Immunotherapeutics keep up with sector leadersMarket Activity Recap & AI Based Buy/Sell Signal Reports - mfd.ru
Biotech investor Cormorant secures $150M for another SPAC deal - BioPharma Dive
(MLTX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Risk Analysis: What is the implied volatility of JWEL2025 Bull vs Bear & High Yield Stock Recommendations - baoquankhu1.vn
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 4.6%Here's What Happened - MarketBeat
Zacks Research Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab - MSN
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
MoonLake Immunotherapeutics (MLTX) Stock Analysis: Exploring a Biotech Innovator’s Growth Potential with an 11% Upside - DirectorsTalk Interviews
MoonLake shares surge after FDA outlines approval route for HS therapy - MSN
Forecast Cut: Can TRINI deliver alphaRate Cut & Risk Managed Investment Entry Signals - baoquankhu1.vn
MoonLake Immunotherapeutics (MLTX) Is Down 7.4% After FDA Clears HS BLA Path Using Existing Trials - simplywall.st
MoonLake Immunotherapeutics (MLTX) Valuation After FDA BLA Green Light And Split Analyst Reactions - simplywall.st
Moonlake surges as no additional studies are required for lead drug - MSN
Lost Money on MoonLake Immunotherapeutics (MLTX)? Contact Levi & Korsinsky Before December 15, 2025 to Join Class Action - TMX Newsfile
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's Why - MarketBeat
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns By Investing.com - Investing.com South Africa
MoonLake downgraded to Sell at Goldman Sachs (MLTX:NASDAQ) - Seeking Alpha
Goldman Sachs Downgrades MoonLake Immunotherapeutics(MLTX.US) to Sell Rating, Raises Target Price to $10 - 富途资讯
Goldman Sachs Downgrades MLTX, Raises Price Target to $10.00 | M - GuruFocus
Goldman Sachs downgrades Moonlake Immunotherapeutics stock to Sell on HS approval concerns - Investing.com Canada
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):